Gianmarco Vannini
Overview
Explore the profile of Gianmarco Vannini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lavacchi D, Fancelli S, Buttitta E, Vannini G, Guidolin A, Winchler C, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902306
Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Unfortunately, nearly half of patients experience disease recurrence despite standard treatments (neoadjuvant and/or...
2.
Palmieri V, Roviello G, Catalano M, DAngelo A, Vannini G, Buttitta E, et al.
Immunotherapy
. 2022 Apr;
14(7):505-510.
PMID: 35380054
Immune checkpoint inhibitors (ICIs) are approved for the treatment of head and neck carcinoma. They have significantly improved survival in these patients but may cause immune-related adverse events (irAEs), some...
3.
Roviello G, Catalano M, Santi R, Palmieri V, Vannini G, Galli I, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503220
Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity and mortality rates. Until recently, the treatment of locally advanced or metastatic urothelial BC was...
4.
Roviello G, Buti S, Cattrini C, Mennitto A, Messina C, Airoldi C, et al.
Ther Adv Urol
. 2021 Jul;
13:17562872211029784.
PMID: 34290828
No abstract available.
5.
Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, et al.
Expert Rev Clin Pharmacol
. 2021 Jul;
14(11):1353-1365.
PMID: 34289756
Introduction: : The evolving therapeutic landscape of advanced hepatocellular carcinoma (HCC) includes the increasing implementation of target-therapy and immunotherapy. Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line...